Healthcare Industry News: Meda AB
News Release - November 14, 2012
New 10 cm GORE(R) Hybrid Vascular Graft Delivers Unprecedented VersatilityIncreased Length of Nitinol Reinforced Section Allows for Access to Deeper Vessels, Extends Landing-Zone Positioning Options
FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)--W. L. Gore & Associates (Gore) has announced the commercial availability of its new 10 cm configuration of the GORE® Hybrid Vascular Graft. The new configuration allows for access to deeper vessels, which expands the treatable patient population and offers exceptional ease of use for physicians performing vascular procedures.
The GORE Hybrid Vascular Graft is indicated for use as a vascular prosthesis for replacement or bypass of diseased vessels in patients suffering occlusive or aneurysmal diseases, in trauma patients requiring vascular replacement, for dialysis access, or for other vascular procedures.
The new configuration features a 10 cm durable Nitinol Reinforced Section that is double the length of the existing 5 cm GORE Hybrid Vascular Graft. The longer extension allows physicians to access even deeper vessels and create new access sites in anatomical locations that would have otherwise been abandoned, preserving the number of access sites available throughout a patient’s long-term therapy.
As with the original GORE Hybrid Vascular Graft, the 10 cm configuration is highly versatile, providing a streamlined solution for several critical vascular procedures.
John R. Ross, MD, General Surgeon, Regional Medical Center in Orangeburg, South Carolina recently performed the first implants of the new 10 cm device for dialysis access. “The new 10 cm Nitinol Reinforced Section of the Gore Hybrid Vascular Graft extends the value of the device by providing minimally invasive access to those vessels that may not have been reachable without major surgery,” Dr. Ross said. “This preserves valuable real estate and provides an ability to revise sites that otherwise would have been abandoned. This is an especially important new option for the dialysis access population.”
Physicians Syed Hussain, MD, Jen Ash, MD and Nabeel Rana, MD, Division of Vascular and Endovascular Surgery, HeartCare Midwest Department of Surgery, University of Illinois College of Medicine in Peoria, Illinois, performed the first arterial bypass procedure in the lower limb using the 10 cm configuration of the GORE Hybrid Vascular Graft. “By integrating a longer Nitinol Reinforced Section into the design of the new Hybrid graft, we are able to access even more difficult-to-reach vessels from more proximal sites, thereby expanding our patients’ treatment options,” Dr. Ash said.
The GORE Hybrid Vascular Graft also offers several advantages for visceral and renal bypasses, noted Jean Bismuth, MD, Vascular Surgeon at The Methodist Hospital in Houston, Texas. “This device provides a distinct advantage in renal bypasses by allowing for a rapid and reliable anastomosis, thereby minimizing renal ischemia,” Dr. Bismuth said. “Additionally, in visceral and renal bypasses, it permits the surgeon to address the anastomosis and atherosclerotic disease of the vessel simultaneously, optimizing flow.”
The GORE Hybrid Vascular Graft combines several trusted Gore technologies. The expanded polytetrafluoroethylene (ePTFE) vascular prosthesis has a section reinforced with nitinol, which is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations. It is the only combination graft of its kind that incorporates CARMEDA® BioActive Surface (CBAS® Surface) with covalently bonded heparin, resulting in a proven thromboresistant surface.
The GORE Hybrid Vascular Graft was launched in the US in May 2011 and in Europe in August 2012. It was recently named the Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA). Since commercialization, more than 3,000 successful implants for dialysis access and other vascular procedures have been recorded.
“The new 10 cm GORE Hybrid Vascular Graft demonstrates our commitment to providing physicians with innovative technology that can expand treatment options and improve patient outcomes worldwide,” said Chuck Biggerstaff, associate with the Gore Venous Access Business.
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 14th consecutive year. www.goremedical.com.
Products listed may not be available in all markets. GORE® and designs are trademarks of W. L. Gore & Associates. CARMEDA® and CBAS® are trademarks of CarMeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.
Source: W. L. Gore
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.